Package 17772-132-07

{"route": ["ORAL"], "spl_id": "453c9f61-1902-44ab-e063-6394a90ab639", "openfda": {"upc": ["0359310210129"], "unii": ["OQW30I1332"], "rxcui": ["2536548", "2536554", "2536750", "2536752", "2536756", "2536758"], "spl_set_id": ["aedf408d-0f84-418d-9416-7c39ddb0d29a"], "manufacturer_name": ["Supernus Pharmaceuticals, Inc"], "is_original_packager": [true]}, "finished": true, "packaging": [{"sample": false, "description": "100 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (17772-132-01)", "package_ndc": "17772-132-01", "marketing_start_date": "20210402"}, {"sample": true, "description": "7 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (17772-132-07)", "package_ndc": "17772-132-07", "marketing_start_date": "20210402"}, {"sample": false, "description": "30 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (17772-132-30)", "package_ndc": "17772-132-30", "marketing_start_date": "20210402"}, {"sample": false, "description": "60 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (17772-132-60)", "package_ndc": "17772-132-60", "marketing_start_date": "20210402"}, {"sample": false, "description": "90 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (17772-132-90)", "package_ndc": "17772-132-90", "marketing_start_date": "20210402"}], "brand_name": "QELBREE", "product_id": "17772-132_453c9f61-1902-44ab-e063-6394a90ab639", "dosage_form": "CAPSULE, EXTENDED RELEASE", "pharm_class": ["Cytochrome P450 1A2 Inhibitors [MoA]", "Cytochrome P450 2B6 Inhibitors [MoA]", "Cytochrome P450 2D6 Inhibitors [MoA]", "Cytochrome P450 3A4 Inhibitors [MoA]", "Norepinephrine Reuptake Inhibitor [EPC]", "Norepinephrine Uptake Inhibitors [MoA]"], "product_ndc": "17772-132", "generic_name": "viloxazine hydrochloride", "labeler_name": "Supernus Pharmaceuticals, Inc", "product_type": "HUMAN PRESCRIPTION DRUG", "brand_name_base": "QELBREE", "active_ingredients": [{"name": "VILOXAZINE HYDROCHLORIDE", "strength": "150 mg/1"}], "application_number": "NDA211964", "marketing_category": "NDA", "marketing_start_date": "20210402", "listing_expiration_date": "20261231"}